Viralgen

Viralgen announced a leadership change on October 19, 2026. Viralgen announced that Angela Ochoa Chico, currently at Bayer, will succeed Jimmy Vanhove as CEO effective January 1, 2027.

What changed

Angela Ochoa Chico was named Chief Executive Officer. Jimmy Vanhove, who led Viralgen for four years, will move to a new role leading the development and expansion of Bayer’s U.S. Pharmaceutical Product Supply Network in New Albany, Ohio.

• Leader: Angela Ochoa Chico
• Role: Chief Executive Officer
• Effective: January 1, 2027
• Announcement date: October 19, 2026

Leadership background

Ochoa Chico most recently served as Product Supply Strategy and Excellence Lead at the Pharmaceuticals Division of Bayer. She has nearly twenty years of international experience across pharmaceutical operations, quality, manufacturing, and strategy. Earlier in her career she led manufacturing and quality organizations in Mexico.

The mandate

In the announcement, Ochoa Chico said she looks forward to building on Viralgen’s strong foundations, advancing its manufacturing capabilities and strengthening its position as a trusted gene therapy manufacturing partner. She said she will work closely with Vanhove and the Viralgen team over the coming months to ensure a smooth transition into the CEO role.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Primary source: Viralgen leadership announcement.